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Abstract: Introduction
Many consequences of cerebrovascular disease are identifiable by magnetic
resonance imaging (MRI), but variation in methods limits multicenter studies and
pooling of data. The European Union Joint Programme on Neurodegenerative
Diseases (JPND) funded the Harmonizing Brain Imaging Methods for Vascular
Contributions to Neurodegeneration (HARNESS) initiative, with a focus on cerebral
small vessel disease.
Methods
Surveys, teleconferences, and an in-person workshop were used to identify gaps in
knowledge and to develop tools for harmonizing imaging and analysis.
Results
A framework for neuroimaging biomarker development was developed based on
validating repeatability and reproducibility, biological principles, and feasibility of
implementation. The status of current MRI biomarkers was reviewed. A website was
created at www.harness-neuroimaging.org with acquisition protocols, a software
database, rating scales and case report forms, and a deidentified MRI repository.
Conclusions
The HARNESS initiative provides resources to reduce variability in measurement in
MRI studies of cerebral small vessel disease.
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ABSTRACT 
Introduction: Many consequences of cerebrovascular disease are identifiable by magnetic 
resonance imaging (MRI), but variation in methods limits multicenter studies and pooling of 
data. The European Union Joint Programme on Neurodegenerative Diseases (JPND) funded 
the Harmonizing Brain Imaging Methods for Vascular Contributions to Neurodegeneration 
(HARNESS) initiative, with a focus on cerebral small vessel disease. 
Methods: Surveys, teleconferences, and an in-person workshop were used to identify gaps in 
knowledge and to develop tools for harmonizing imaging and analysis. 
Results: A framework for neuroimaging biomarker development was developed based on 
validating repeatability and reproducibility, biological principles, and feasibility of 
implementation. The status of current MRI biomarkers was reviewed. A website was created 
at www.harness-neuroimaging.org with acquisition protocols, a software database, rating 
scales and case report forms, and a deidentified MRI repository.  
Conclusions: The HARNESS initiative provides resources to reduce variability in 
measurement in MRI studies of cerebral small vessel disease. 
 
 
INTRODUCTION 
Vascular disease contributes to more than half of dementia cases, often in conjunction with 
Alzheimer’s disease pathology1. Most of the vascular brain injury is caused by cerebral small 
vessel disease (cSVD)2, which often goes clinically unrecognized until revealed by brain 
imaging. cSVD is strongly associated with cognitive impairment and future risk for cognitive 
decline and dementia3,4. One of the challenging but intriguing aspects of research in this field 
is that cSVD has diverse manifestations, including brain infarcts, lacunes, white matter 
hyperintensity (WMH) of presumed vascular origin, perivascular spaces, and microbleeds5. 
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Additionally, several promising new imaging biomarkers are emerging for the diagnosis and 
monitoring of patients, as well as for studies into etiology and pathophysiology6,7. 
The Standards for Reporting Vascular Changes on Neuroimaging (STRIVE)5 were an 
important first step to harmonize neuroimaging assessment of cSVD. Terms and definitions 
for common cSVD lesion types, reporting standards, and suggestions for acquisition 
protocols were provided, and are now commonly used in research practice. However, 
STRIVE did not address pathways for developing and validating new biomarkers, nor did it 
address sources of variability in measurement, which should be minimized to enhance the 
ability to detect biological differences in multicenter and longitudinal studies. 
To fully realize the potential of neuroimaging biomarkers of cSVD for use in larger 
scale, multicenter studies including clinical trials with cSVD endpoints, we created the 
Harmonizing Brain Imaging Methods for Vascular Contributions to Neurodegeneration 
(HARNESS) initiative. This initiative builds on the work of STRIVE by defining a 
framework for developing neuroimaging biomarkers of cSVD, reviewing the status of 
emerging neuroimaging biomarkers in this field, and developing and implementing 
standardized acquisition protocols and web-based repositories to facilitate multi-center 
research.  
 
METHODS 
HARNESS Group Composition 
HARNESS was funded by the international Joint Programme for Neurodegenerative Diseases 
initiative to address neuroimaging biomarkers in neurodegeneration and dementia. The 
HARNESS members were invited to participate based on contributions cSVD research 
including their participation in STRIVE, and to provide a balance of input from different 
geographic regions and research disciplines. HARNESS included 70 members from 29 
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institutions in 11 countries, representing disciplines including radiology, biomedical 
engineering, clinical trials, computer science, epidemiology, medical biophysics, neurology, 
stroke medicine and psychiatry. Members were surveyed to identify important needs for 
harmonizing neuroimaging methods for cSVD, and then subdivided into 11 working groups 
of 6-12 participants representing a range of disciplines, cSVD interests and location, to 
address these needs. The initiative commenced in July 2016 and culminated in an in-person 
conference in June 2017. Where appropriate, working groups identified relevant papers 
through literature searches, expert knowledge, and hand searching articles from reference 
lists, but formal systematic reviews and creation of evidence tables were considered out of 
scope.   
 
RESULTS 
Neuroimaging Biomarker Framework for cSVD 
We adopted the definition of a biomarker used by the Biomarkers Definitions Working 
Group8: “a characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention”. Inherent to this definition is that biomarkers may have different clinical 
purposes including diagnosis, prognosis, monitoring, and measuring treatment response. 
Biomarkers have been used as surrogate endpoints for clinical trials, meaning that the 
biomarker substitutes for or represents a manifestation of the clinical endpoint, when the 
biomarker is expected to predict “clinical benefit or harm based on epidemiologic, 
therapeutic, pathophysiologic, or other scientific evidence”9. This might be considered the 
highest level of qualification for a biomarker. However, biomarkers have other important 
uses for investigation, diagnosis, and monitoring of disease even if they do not predict 
treatment response. 
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Validation is required to determine whether a biomarker can be considered fit for a 
specific purpose. Some regulatory authorities, such as the U.S. Food and Drug 
Administration (FDA), define a formal process of biomarker qualification for use in 
evaluating therapeutics10. To our knowledge, no biomarker of cSVD, including WMH, 
lacunes, or microbleeds, has yet been submitted to and qualified by the US FDA for use in 
clinical trials, although they have been used as secondary endpoints in imaging substudies11. 
Qualification of an imaging marker that can be used as a trial endpoint would greatly 
accelerate the development of therapies for cSVD by improving selection criteria, reducing 
the size and cost of a trial and increasing the specificity of the outcome. 
To facilitate validation of cSVD biomarkers we present a framework for 
neuroimaging biomarker development in Figure 1, adapted from consensus recommendations 
from the European Society of Radiology12 and for development of imaging biomarkers for 
oncology13. Validation has technical aspects (e.g., can the same measurement be reproduced 
reliably on the same scanner or different scanners?), biological aspects (e.g., is the 
measurement different in patients with vs. without cSVD?), and feasibility of implementation 
(e.g., is the measurement practical and affordable?). In our version of this biomarker 
development framework, we define proof of concept as validation of measurement of a 
specific change or process (e.g., that arterial spin-labeling [ASL] MRI generates a signal that 
correlates with gold standard measurement of perfusion) while proof of principle refers to 
validation that the measurement distinguishes cases from controls or is associated with health 
outcomes (e.g., that ASL measured perfusion is different in cSVD patients than in controls 
and is associated with worse prognosis)12. We define proof of effectiveness as the ability to 
measure the marker across larger groups of patients at multiple sites12. Repeatability refers to 
the precision of repeated measurements under the same conditions using the same scanner 
(with high repeatability conferring greater power to detect smaller within-individual changes 
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over time, important for longitudinal studies), while reproducibility refers to the precision of 
replicate measurements on the same or similar objects (e.g. a phantom or human volunteers) 
using different scanners12,13. For visual assessments by human raters, intra-rater reliability 
refers to the precision of measurement by the same rater while inter-rater reliability refers to 
the precision of measurements across different raters. The Quantitative Imaging Biomarker 
Alliance (QIBA) offers recommendations for study design and statistical approaches to 
technical validation14. Validation typically begins with relatively small, cross-sectional 
studies at single centers to demonstrate proof of concept, proof of principle and initial 
technical validation, before expanding to longitudinal studies and multicenter studies to 
demonstrate proof of effectiveness and reproducibility. Feasibility is then demonstrated by 
incorporation of the biomarker into clinical radiological practice or by qualification for use in 
clinical trials. 
 
Survey of Current cSVD Biomarker Development with Specific Considerations for 
Selected Emerging Modalities  
Commonly studied neuroimaging biomarkers of cSVD are lacunes, WMH of presumed 
vascular origin, and cerebral microbleeds. These lesions are typically reported in routine 
radiology practice and have been incorporated as secondary imaging endpoints in some 
clinical trials. For these markers proof of concept, principle, and effectiveness have been 
established. Even so, longitudinal data on change over time and data on repeatability and 
reproducibility, so important for planning sample sizes in clinical trials, are relatively 
scant15,16.   
 A recent systematic review highlighted the gaps in knowledge in repeatability and 
reproducibility of measurements of cSVD lesions, focusing mostly on quantitative 
biomarkers including volumes of WMH, lacunes, and brain17. The authors systematically 
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searched the literature to identify information on scan-rescan repeatability (which they 
termed “within center reproducibility”) as well as the effects of scanner vendor, field 
strength, sequence choices, and coil type. They found that the amount of literature on 
repeatability and reproducibility varied widely by lesion type. The most literature was found 
on measures of brain volume, probably because brain atrophy is an important biomarker for 
many neurological diseases in addition to cSVD, such as Alzheimer’s disease, and because 
phantoms are available for measuring variations in geometric distortions across scanners. For 
WMH, lacunes, perivascular spaces, and microbleeds there was only sparse information on 
repeatability with relatively speaking the greatest amount of information on WMH 
measurements cross-sectionally, but no repeatability data on longitudinal measurements.  
Figure 2 provides an overview of the validation status of the best established cSVD 
markers as well as emerging modalities and techniques. Over time the list of neuroimaging 
biomarkers of cSVD has grown substantially as our knowledge of cSVD pathophysiology2, 
and ability to image it, has grown.  
Some markers have already received a large amount of attention, notably WMH 
(assessed visually or computationally), lacunes, and microbleeds (mainly visually with some 
emerging computational methods). Even so, some aspects of validation are lacking with few 
large comparisons of different volumetric tools, little longitudinal data, and none are yet 
adopted as confirmed surrogate outcomes in clinical trials. Nonetheless, they have already 
been the subject of many reviews16,17.  
Hence, the list of biomarkers discussed in detail here represents the subset that the 
HARNESS group selected as the next most promising for measuring unique aspects of cSVD 
pathophysiology, but that have so far received less attention. The list is not exhaustive. Future 
research will likely add more modalities and lesion types. For example, microinfarcts have 
been visualized on MRI by several research groups and may be a frequent but 
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underrecognized consequence of thrombosis or embolism of small arteries18. Additionally, 
future research may clarify that biomarkers currently on the list are a poor fit for some 
purposes.  
In the following sections, we review the state of imaging biomarker development for 
selected emerging modalities, along with considerations for further development and 
harmonization. 
Structural Imaging: Perivascular spaces  
Perivascular spaces are rapidly emerging as a novel marker of cSVD and are defined as 
“fluid-filled spaces that follow the typical course of a vessel as it goes through grey or white 
matter”5. While long considered an innocuous phenomenon of aging, a converging body of 
proof of principle cross-sectional studies now suggests that a larger burden of perivascular 
spaces is associated with a higher likelihood of dementia, cognitive impairment, and stroke19-
21 More importantly, these associations are independent from established markers of cSVD. 
Longitudinal studies of the appearance of perivascular spaces or their enlargement over time 
are lacking; therefore, the rate at which these spaces change over time is essentially unknown. 
One study showed that the 5-year incidence of new large perivascular spaces (defined as ≥3 
mm diameter) in a general elderly population was 3.1%21, however this size exceeds the 
generally accepted current width boundary between perivascular spaces and lacunes5.  
There are few data on the repeatability of measurements of perivascular spaces and 
reproducibility of measurement across scanners. For one automated method, repeatability was 
excellent with intra-class correlations of 0.92 for basal ganglia and 0.87 for centrum 
semiovale22. In contrast, intra-rater and inter-rater reliability for visual rating scales have been 
published by several groups and should be expected to be good to excellent (i.e., with kappa 
values of 0.5 or higher or intra-class correlation coefficients of 0.6 or higher). Rating on T2-
weighted sequences is favoured because perivascular spaces are well visible, but some 
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studies have used high resolution T1-weighted sequences instead. In one study, ratings on 
T1-weighted and T2-weighted sequences showed excellent correlation (intraclass correlation  
>0.80)23. 
The HARNESS working group identified several difficulties in the quantification of 
perivascular spaces, which have so far hampered comprehensive understanding of their 
biological meaning. First, perivascular spaces, reflecting the virtual space between blood 
vessels and pia mater, by themselves are a physiologic finding. It is the enlargement of these 
spaces that can be visible on MRI that is considered non-physiologic. The question then 
remains what amount of enlargement should distinguish physiologic from non-physiologic 
perivascular spaces? Originally, a convenience threshold was chosen, such that any 
perivascular space visible on brain MRI was considered enlarged. However, increasing field 
strengths and other advances in imaging now allow much smaller perivascular spaces to 
become visible on MRI, indicating the need to use a more objective and reproducible 
threshold independent from imaging parameters. 
Second, since perivascular spaces are defined by their intricate relation to brain 
vessels, they are ubiquitous in all brain regions. Yet, the extent of enlargement is different 
across brain regions and should be taken into account in their quantification. A working 
upper width limit of 3 mm is widely used to discriminate perivascular spaces from small 
lacunes5, but for example it is well recognized that larger width perivascular spaces are 
sometimes seen in the substantia innominata. Radio-pathological correlation studies show 
that MRI can differentiate perivascular spaces from lacunes with good sensitivity and 
specificity using morphological and signal intensity information24, but more validation on 
correlations by region would be welcome. Similarly, the processes underlying their 
enlargement are thought to differ according to brain region; for example, in cerebral amyloid 
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angiopathy enlargement of perivascular spaces is seen in the centrum semiovale but not in the 
basal ganglia.25,26. 
Against this background, it is not surprising that the various efforts to quantify 
perivascular spaces have differed with respect to definition of enlargement, regions to be 
scored, and scoring system used23,27-30. While work continues to identify the key features of 
these rating systems with respect to similarities, dissimilarities, strengths, weaknesses, and 
‘translation’ from one rating system to the other, we recommend that investigators use the 
rating system most relevant to their population, or that they are most comfortable with, while 
having a core understanding how that specific rating system relates to others available in the 
literature. Raters should be trained on a standardized dataset with measurement of intra-rater 
and inter-rater reliability and report these measures in publications; training tools are 
available on HARNESS website.  
Parallel to this development of visual rating, there is now a strong focus on fully-
automated quantification of perivascular spaces. These efforts have so far been hampered by 
similar methodological considerations as outlined above, but the recent introduction of 
machine learning algorithms in brain imaging holds great promise in overcoming these 
barriers22,31. Just like automated quantification of WMH resulted in dramatic improvement in 
our understanding of their role in neurodegenerative diseases particularly at the voxel level, 
automated detection, volumetrics, shape, density and orientation of perivascular spaces could 
signify a paradigm shift in their position within the pantheon of cSVD markers. 
Structural Imaging: Atrophy in the context of cSVD  
Atrophy is now a well-established, measurable consequence of cSVD. Both cross-
sectional and longitudinal studies show proof of principle that total brain volume is lower in 
cSVD and decreases more quickly in persons with enlarging WMH. The repeatability and 
reproducibility of brain volume measurements in the context of cSVD has been reviewed 
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recently17. Here, we highlight specific aspects to be considered when implementing atrophy 
measurements in cSVD studies.  
Given the complexity of brain anatomy, measures of brain volume should be obtained 
from 3D T1-weighted high-resolution isotropic sequences with quantitative computerized 
methods where possible. To capture chronic, final effects, the image acquisitions should be 
performed remotely in time (probably 90 days or longer) from the occurrence of acute brain 
lesions.  
At a given time point, volumetric measures reflect the sum of the individual’s 
maximum brain volume growth (estimated by the intracranial cavity volume), the effect of 
age, and that of multiple potential diseases including cSVD, overt stroke, and 
neurodegenerative diseases such as Alzheimer’s disease. Controlling for differences in head 
size, e.g. by expressing volumes as a fraction of intracranial volume or including intracranial 
volume as a covariate, is mandatory in single time point analyses. Although controlling for 
intracranial volume is not strictly necessary for longitudinal analyses, investigators may still 
want to analyze it as a proxy for original maximum brain size which reflects premorbid brain 
health and is associated with general intelligence32. In longitudinal analyses, the use of cross-
timepoint registration pipelines rather than repeated use of cross-sectional methods may 
reduce variability in measurement33,34 but the optimal approach remains to be confirmed.  
Methods involving registration to a common template should be used cautiously given 
that brains with cSVD, often exhibiting large ventricles and white matter atrophy, can register 
poorly to atlases based on healthy individuals. This is a particularly challenging problem 
when cSVD is accompanied by larger destructive intracerebral hemorrhages or infarcts. The 
impact of brain tissue lesions on the different methods to assess brain volume is often 
unpredictable35. In particular, the presence of extensive WMH can lead to erratic behavior of 
most algorithms,36,37 and if appropriate they should be masked. Additionally, algorithms may 
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variably segment fluid-filled cavities within the brain (lacunes and enlarged perivascular 
spaces) as cerebrospinal fluid, gray matter or white matter, requiring a systematic visual 
quality control of segmentation results35,38. There is consensus that cavities resulting from 
infarction should be excluded from brain tissue estimates5, depending on the question being 
asked; clearly, they do not represent spaces such as subarachnoid space or ventricles but nor 
do they represent normal brain tissue. They can be considered as part of the ‘total burden of 
brain injury’39 in some analyses. Quantitative methods are emerging that can estimate 
perivascular space volume; when such measurements are made we recommend that 
perivascular space volume be reported as a separate tissue class and not included in the total 
brain volume. Given the numerous sources of variation in gray to white contrast in cSVD, 
differential measures of gray and white matter volumes should be interpreted carefully40. The 
use of other computational volumetric markers, such as ventricle volumes, has not been 
validated in cSVD. All methods require visual checking and may need manual editing where 
automated segmentation has failed to identify the correct tissue. 
Diffusion imaging metrics 
Diffusion imaging provides of the diffusion of water molecules within brain tissue. 
There are a large variety of techniques to analyze these data. Diffusion-weighted imaging is 
positive (that is, shows increased signal) in the setting of recent infarction or microinfarction. 
Scalar measures describe diffusion properties on the voxel level, such as the extent or 
directionality. Diffusion tensor imaging (DTI) is the most useful model to derive these scalar 
metrics such as mean diffusivity (MD) or fractional anisotropy (FA). Tractography can be 
used to visualize fiber connections and analyze diffusion on the tract level. Global 
tractography in combination with graph theoretical network analysis allows to assess the 
impact of cSVD on the level of brain networks. 
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Proof of principle that diffusion imaging metrics can serve as biomarkers of cSVD is 
well established by multiple studies associating diffusion imaging indices derived from the 
white matter (WM) or normal-appearing WM (NAWM) with cSVD and cSVD risk factors. 
Most studies report cross-sectional associations between lower FA or higher MD and 
cognitive and gait impairments41,42 Mean diffusivity is readily measured in the whole brain, 
tissue subregions, regions of interest or tracts and shows the strongest associations with SVD 
lesion burden43. Recent, promising post-processing methods to increase the reliability and 
ease of extraction of diffusion imaging metrics include histogram-derived diffusion imaging 
metrics, such as the peak width of the skeletonized MD distribution (PSMD)44, and 
connectivity measures including ones based on network theory45-47. Lower brain connectivity 
in strategic network locations, such as long-distance fibers connecting so-called network 
‘hubs’, show promise for prediction of speed and executive functioning48,49. This is not an 
exhaustive list, as there are several other promising diffusion imaging acquisition and 
analysis methods which show promise for development as biomarkers of cSVD50,51. 
In contrast to the many cross-sectional studies, there are fewer studies evaluating 
diffusion imaging as a prognostic marker of disease progression.41 The LADIS study reported 
an association between NAWM MD at baseline and decline in processing speed,52 whereas 
the RUN DMC study found no association between baseline NAWM MD and cognitive 
decline53, or risk of dementia over 5 years54. Diffusion imaging-derived brain connectivity 
predicted conversion to dementia after 5 years55. Longitudinal studies of diffusion imaging 
change over time are at this time relatively scarce56-60 but promising, suggesting that change 
over time can be detected on diffusion imaging with similar sensitivity as change over time in 
WMH volume, requiring smaller sample sizes than required to detect atrophy or incident 
lacunes61. Progression over time in diffusion imaging metrics has been associated with 
increased risk of dementia58 and gait decline62. 
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The tissue correlate of altered diffusion metrics in cSVD is still debated. A recent 
study suggests that increased extracellular water content is a major contributor50. 
There are few studies on repeatability and reproducibility. The only study in patients 
with cSVD showed high reproducibility of PSMD in 7 patients with CADASIL scanned on a 
1.5T and 3T scanner (intraclass correlation 0.95)44. Other studies in healthy controls have 
shown good repeatability and reproducibility for FA and MD measurements (coefficient of 
variation ranging from 0.8 to 5.7%)63-65. Nonetheless, variation in scanner or scanner 
upgrades may bias measurements in longitudinal studies63; therefore, investigators ideally 
should avoid scanner upgrades or changing scanners between baseline and follow-up 
measurements in studies designed to detect small changes over time. Phantoms to estimate 
reproducibility are in development.66 
Perfusion and cerebrovascular reactivity  
Perfusion and cerebrovascular reactivity (CVR) approaches are highly relevant in cSVD 
research because reduced tissue perfusion and impaired CVR are hallmark pathological 
features. These physiological forms of imaging introduce a unique set of challenges for study 
design, given the large variability in acquisition methods for perfusion and especially CVR 
which are less well established compared to many structural imaging techniques. To image 
CVR, the investigator must choose among several experimental methods for stimulating 
changes in cerebral blood flow (CBF), as well as between several different acquisition types 
such blood oxygen level dependent (BOLD) or arterial spin labeling (ASL). Because the 
vascular signal comes from only a proportion of voxel contents (the blood volume fraction in 
grey matter accounts for 5 to 10% of the tissue volume), and for BOLD-related techniques 
the changes in hemoglobin oxygenation are relatively small, attention must be paid to ensure 
sufficient signal to noise ratio to generate images of adequate quality. 
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 Dynamic susceptibility contrast (DSC) and ASL are examples of MRI acquisitions 
that yield perfusion-weighted images; the former relies on an exogenous gadolinium contrast 
agent, while the latter uses magnetically labeled arterial blood water that is proximal to the 
imaging volume to label blood and produces quantitative perfusion maps typically expressed 
in units of mL/100g tissue/minute.  
ASL is a promising modality for repeated measure studies because it does not require 
administration of an exogenous intravenous contrast agent. A fraction of cSVD articles on 
perfusion have thus far used ASL67; cross-sectional studies, for example, provide proof of 
principle by showing that a pattern of reduced frontal perfusion was associated with increased 
WMH volume68. Longitudinal studies are less common, however, one 4-year follow-up study 
reported that global CBF decreases were associated with higher baseline WMH but that 
baseline CBF was not associated with greater WMH progression.69 Another longitudinal 
study found that while lower baseline CBF predicted appearance of new WMH at 18 months, 
change in CBF was not associated with new WMH70. Studies are needed on the association of 
baseline and longitudinal CBF and the prevalence and incidence of new brain infarcts and 
microinfarcts. Although white matter and subcortical tissue perfusion estimates are of 
particular interest in cSVD, these measurements are less robust than in grey matter when 
using ASL71 due to the lower CBF and longer arterial transit time.   
A validation study of ASL found higher repeatability for pseudo-continuous ASL 
compared with pulsed ASL or continuous ASL, with a coefficient of variation of 3.5% in 
gray matter and 8.0% in white matter72. There are few reproducibility studies across scanner 
types. One study found high reproducibility in eight volunteers scanned on two General 
Electric (GE) 3T scanners73. Another study found that sequence parameter differences had a 
larger effect than hardware or software differences on General Electric, Philips, and Siemens 
scanners74. Phantoms for ASL have been developed but not yet widely adopted75. 
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 Unlike physiological imaging during a single “baseline” state, CVR involves 
physiological provocation to measure a vasoactive response, typically by breathing medical 
air enriched with carbon dioxide gas. Technical and paradigm details and considerations have 
been recently reviewed76. Multi-contrast physiological imaging, combining perfusion and 
CVR maps in cSVD, is a promising technique77. At this time, relatively few CVR studies 
have focused explicitly on cSVD78. However, CVR imaging is being exploited as an imaging 
endpoint to assess the efficacy of vasodilatory drugs in a dose escalation trial79. CVR appears 
to be a promising prognostic biomarker of cSVD brain changes, for example as revealed by 
one longitudinal study that found impaired regional CVR was predictive of WMH lesion 
expansion at one-year follow-up80. A four-year longitudinal study showed that age-related 
decreases in CVR were associated with steeper declines in processing speed and episodic 
memory but not working memory or reasoning; however, the degree to which enlarging 
WMH or new infarction may have been associated with these changes was not assessed. The 
BOLD-response to a visual stimulus has been shown to be a possible biomarker for CAA and 
could be a more easily implemented, well-tolerated alternative means to measure CVR, but is 
is limited to the occipital lobe81-83 and has not been compared directly to CVR measurement 
based on hypercapnia. 
 The repeatability of CVR measurements has been investigated in healthy controls but 
not patients with cSVD. In a study of 15 controls, the coefficient of variation ranged from 
7.3% to 42.9% across 16 regions of interest including cortical and subcortical grey matter and 
white matter84. The coefficient of variation was lower when using a paradigm that averaged 
two three-minute blocks of CO2 inhalation rather than three one-minute blocks
84. 
 A consensus group has provided recommendations for ASL imaging protocols85; 
however, long-label and long-delay ASL approaches may prove superior for CBF 
measurement in the white matter and subcortical gray matter. Multicenter studies using 
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scanners from different vendors seems justifiable as long as key methods (including choice of 
pseudo-continuous ASL, readout strategy, labeling duration, and post-labeling delay time) are 
kept constant. For CVR imaging, there are a greater diversity of methods and the different 
methods may suit specific patient populations. One published protocol84 using three-minute 
CO2 blocks is being used in a multicenter trial. 
Blood-brain barrier integrity 
Although proof-of-concept evidence is very limited, proof-of-principle evidence from cross-
sectional clinical studies suggests that blood-brain barrier (BBB) dysfunction determined by 
MR is associated with imaging features of cSVD, and that BBB leakage may contribute to 
tissue damage, development of cSVD features and long-term adverse outcomes86,87. 
Therefore, BBB permeability is an important target of measurement in studies of 
pathophysiology and treatment evaluation. 
Dynamic contrast-enhanced MRI (DCE-MRI) using a standard dose of a gadolinium-
based contrast agent is presently the most promising technique for quantitative imaging of 
subtle leakage86, and has been applied in several studies of cSVD and related conditions.86,88-
91 However, while the technique is well-established in other conditions such as brain tumours, 
particular challenges emerge in cSVD due to the slow rate of leakage. For qualitative 
assessment, gadolinium-based contrast agent (GBCA) enhancement of cerebrospinal fluid on 
T2-weighted fluid attenuated inversion recovery (FLAIR) and T1-weighted imaging may 
provide a practical, though non-specific, alternative92,93. Other potential methods are difficult 
to quantify (e.g. dynamic susceptibility contrast MRI),94 employ ionising radiation,95,96 or are 
at an early stage of development (compartmental ASL modelling97-99). Nevertheless, DCE-
MRI is not routinely used in cSVD studies due to practical impediments (long scan time, 
exogenous contrast), lack of widespread expertise, and technical and physiological 
complexities and confounds100,101.   
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There are few studies of BBB permeability change over time in cSVD. A single study 
of 22 subjects with high WMH burden reported little overlap between regions of high white 
matter permeability between the first and second scan, but that high permeability was often 
seen along the border of WMH at either time102. 
Because there is no reliable convenient reference method for quantifying subtle BBB 
permeability, studies comparing DCE-MRI measurements with other measures of BBB 
integrity are few and inconclusive103,104. The need for a second gadolinium administration is a 
barrier to conducting studies on repeatability, but one study showed good evidence of 
repeatability with coefficient of variation of 11.6 % for white matter and 14.4 % for gray 
matter at 3T105. Reproducibility across different MR hardware has not been investigated. 
Based on theoretical considerations and experimental observations, it is likely that 
measurements are influenced by MR field strength, scanner stability, spatial resolution, pulse 
sequence parameters, acquisition time, GBCA type, and pharmacokinetic model100,101,106,107. 
The diversity of acquisition and analysis protocols described (sometimes incompletely) in the 
literature is, therefore, a key impediment to the interpretation and comparison of data from 
different studies and centres. 
Our recommendation for future studies is to use a three-dimensional, MR acquisition 
with wide spatial coverage, pre-contrast T1 measurement, a minimum temporal resolution of 
around one minute and minimum DCE scan time of 15 minutes108. A vascular input function 
should be measured in the venous sinuses and the permeability-surface area product PS for 
tissue regions or, where feasible, individual voxels should be estimated using an appropriate 
pharmacokinetic model, typically the Patlak model109; simulations may be performed to 
assess accuracy and precision. Results should be interpreted carefully, particularly when 
comparing data from different research groups or scanners. We identify three priorities for 
the development of this biomarker: (i) agreement by the wider cSVD and dementia imaging 
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research community on an open-access, dynamic consensus protocol for DCE-MRI 
measurements of slow BBB leakage, (ii) acquisition of data on repeatability and 
reproducibility, and (iii) studies to assess accuracy, including theoretical work, comparison 
with independent measures of BBB integrity, and validation using MR test objects and 
histology. Further technical development to increase accuracy and precision, as well as 
continued development of alternative methods are also encouraged. 
Ultra high field MRI 
Ultra-high field MRI, in particular 7T MRI, is emerging as a new tool in cSVD research. The 
higher resolution, different tissue contrasts, and better signal to noise ratios of 7T MRI allow 
the investigator to probe aspects of cSVD that are difficult to assess at lower field strength. In 
addition to enhanced sensitivity for cSVD lesions such as microinfarcts and microbleeds and 
more precise assessment of atrophy18,110, with 7T MRI it is possible to actually visualize the 
small vessels111.  From both perforating arteries and veins features such as vessel density, 
length, and tortuosity can be resolved.111,112. Additionally, different aspects of vascular 
function, including blood flow, pulsatility of flow in small penetrating arteries (a possible 
indicator of vascular stiffness), vascular reactivity to vasoactive agents (e.g carbon dioxide) 
or neuronal stimulation (i.e. functional MRI), can be assessed, making it possible to probe 
cSVD at the level of the small vessels themselves111. 
Despite the potential for of 7T MRI for cSVD, important steps have to be taken to 
validate these novel techniques. Of note, EUFIND (the European Ultrahigh-Field Imaging 
Network in Neurodegenerative Diseases), another JPND initiative, has the goal of 
harmonizing 7T MRI protocols across more than 20 centres from Europe and the US.  
 
Tools to Facilitate cSVD Biomarker Development and Harmonization 
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 The HARNESS initiative focused on three areas to provide tools for harmonization: 
MR acquisition, post-processing, and common repositories for training and validation. These 
tools are made available to the research community at www.harness-neuroimaging.org. 
 The HARNESS website provides fully specified MR acquisition protocols suitable for 
research studies that include a focus on cSVD. Given the diversity of manifestations of cSVD 
and hypotheses that can be tested, there is no single MR acquisition protocol that can quantify 
all aspects of cSVD and therefore investigators must make choices regarding protocol 
composition, also accounting for issues of feasibility including acquisition time and cost. 
Therefore, instead of a single protocol the HARNESS website provides several options that 
meet these criteria: a) they adhere to STRIVE5, b) they are suitable for identifying canonical 
cSVD lesions types--lacunes and WMH of presumed vascular origin, recent small infarcts, 
microbleeds, atrophy, and DTI changes, c) they have been tested on more than one scanner as 
part of an established multicenter study and d) the protocol developers are willing to share the 
protocol freely. There are also links to other websites and useful repositories of information. 
Currently, protocols are available from the SVD@target study84 (ISRCTN10514229) 
and the Canadian Dementia Imaging Protocol113, with plans to add the protocol from the U.S. 
National Institute of Neurological Disorders and Stroke MarkVCID Biomarker Consortium 
(https://markvcid.partners.org/) once it has been fully specified and tested. Sequence 
parameters with exam cards are provided for 3T for most of the major vendors including 
General Electric, Phillips, and Siemens. The protocols are suitable for prospective research 
studies with quantitative imaging biomarkers but probably exceed most clinical stroke 
protocols in terms of acquisition time, spatial resolution, and inclusion of DTI. They have 
been implemented successfully in multicenter studies at research sites, but nonetheless may 
not be feasible for multicenter studies performed at predominantly clinical scan sites where 
the intent is to leverage clinical imaging without a focus on quantitative biomarkers.  
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 Reducing imaging variability may be enhanced by following consensus 
recommendations17 to perform automated quality checks for acquisition parameters and 
monitoring of images for artefacts, correction for gradient nonlinearities, a well-defined 
method for subject’s positioning in the scanner, and a clear strategy for hardware replacement 
when needed.  
 The HARNESS software database provides a searchable source for information on 
downloadable software tools for processing MR data for cSVD quantitative biomarkers, such 
as for segmenting WMH. There are many existing software libraries for neuroimaging 
analysis, but only HARNESS focuses exclusively on cSVD. Site users can search for 
software by image modality, measurement type, key words, availability (i.e. by download or 
by request to the developer), or operating system. Software developers control their own 
entries via password-protected accounts, and must make their software available according to 
their own terms by providing a link or through contacting the developer. We are actively 
recruiting developers with tools to sell or share. Developers may access the site for 
information on how to create accounts. 
 To aid visual review for cSVD lesions according to STRIVE, the HARNESS site 
makes downloadable electronic documents available including validated visual rating scale 
scores and instructions, case report forms, and training slides. 
 Training readers and software algorithms requires access to independent MR datasets 
for measurements. The HARNESS site includes a web-based repository with completely de-
identified 3T MR data showing lacunes, WMH, microbleeds, and cortical superficial 
siderosis from patients with TIA, minor ischemic stroke, and cerebral amyloid angiopathy, 
with consensus “gold standard” measurements for comparison. This repository will be useful 
for independently confirming reliability of measurements within and across research groups, 
and for derivation and validation of computerized algorithms for quantitative measurement 
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(e.g. for segmenting WMH to determine location and overall volume) as well for comparing 
WMH algorithms against an independent standard. 
 
SUMMARY AND CONCLUSIONS 
 The HARNESS initiative was a multidisciplinary consensus process with input from a 
large number of neuroimaging researchers investigating cSVD. Our group developed a 
framework for neuroimaging biomarker development closely aligned with those proposed in 
other areas of imaging research. The HARNESS website (www.harness-neuroimaging.org) 
was created to facilitate harmonized neuroimaging methods for cSVD research.  The site 
includes cSVD-appropriate MR acquisition protocols aligned with STRIVE, a searchable 
database of softwares for analyzing brains with cSVD, visual rating scales and case report 
forms, and a repository of 100 deidentified scans demonstrating different cSVD lesion types. 
These tools and resources are made available to the research community via the site and can 
be easily updated by contributors. 
 In this rapidly evolving field, we found that the degree of biomarker validation—
technical, biological and clinical, and feasibility—varied by cSVD lesion and measurement 
type. In general, visually diagnosed cSVD lesions such as lacunes, WMH, and microbleeds 
have the greatest amount of clinical validation including as prognostic markers and data are 
available on incidence andchange over time, and are already being used in multicenter studies 
and reported in routine clinical practice. Even so, none of these markers has yet been 
qualified for use in clinical trials by regulatory agencies, and more work is needed to 
standardize and compare current volumetric tools. Other markers are at a less advanced stage 
of biomarker development. Atrophy has been extensively studied but almost always in the 
context of Alzheimer’s disease and not cSVD. Among the emerging cSVD markers there are 
relatively more data on diffusion imaging and perivascular space imaging, but more 
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longitudinal data and multicenter data on reproducibility are needed. Measurements of brain 
perfusion, vascular reactivity, and blood-brain barrier integrity are promising but are at an 
even earlier stage of development. For these cSVD manifestations innovation to overcome 
technical and feasibility barriers, rather than harmonizing to a best protocol, is the most 
important next step in development. 
 We found that technical validation often lagged clinical validation. However, 
estimates of repeatability and reproducibility are critically important to estimate minimum 
detectable differences over time and variability in measurement in multicenter studies, 
essential for sample size calculations for multicenter longitudinal trials. This lag in technical 
validation likely reflects the difficulty in obtaining funding for technical studies compared to 
clinical studies, the burden on research subjects to undergo multiple scans, and the general 
lack of non-human phantoms for studies of reproducibility. In contrast to volumetric imaging 
and functional MRI, phantoms for other measurements are less well developed. One research 
group has developed a phantom for iron deposits that mimic mineral deposits and 
microbleeds, not currently available for purchase114; otherwise, we are not aware of any other 
phantoms that recreate specific aspects of cSVD. Technical validation for neuroimaging 
biomarkers of cSVD would be enhanced by creating funding opportunities specifically for 
this purpose. 
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Figure 1. Imaging Biomarker Development Framework for Cerebral Small Vessel Disease 
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Figure 2. Schematic overview of neuroimaging biomarker development status for cerebral 
small vessel disease 
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Figure 2 Legend: Green light indicates validation data from two or more studies from 
independent research groups; Yellow light indicates support from a single study or 
conflicting evidence from multiple studies; Red light indicates there is currently insufficient 
evidence. WMH, white matter hyperintensities of presumed vascular origin; CMB, cerebral 
microbleeds; PVS, perivascular spaces; DTI, diffusion tensor imaging; BBB, blood-brain 
barrier. Proof of concept: evidence that the marker measures a specific change or process 
related to cerebral small vessel disease.  Proof of principle/ Mechanism: evidence that the 
marker differs between patients with and without cerebral small vessel disease. Proof of 
effectiveness: evidence from larger scale multiple center studies that the marker differs 
between patients with and without cerebral small vessel disease. Repeatability: precision of 
repeated measurements under the same conditions using the same scanner. Reproducibility: 
replicate measurements on the same or similar objects (e.g. a phantom or human volunteers) 
in different locations using different scanners. Longitudinal: rate of change over time has 
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been defined. Monitoring: evidence that longitudinal change in the marker is associated with 
progression of cerebral small vessel disease. Surrogate: evidence that change in the marker is 
strongly associated with clinical outcomes in cerebral small vessel disease, such that changes 
in the marker could be considered a substitute for a clinical endpoint.  
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ABSTRACT 
Introduction: Many consequences of cerebrovascular disease are identifiable by magnetic 
resonance imaging (MRI), but variation in methods limits multicenter studies and pooling of 
data. The European Union Joint Programme on Neurodegenerative Diseases (JPND) funded 
the Harmonizing Brain Imaging Methods for Vascular Contributions to Neurodegeneration 
(HARNESS) initiative, with a focus on cerebral small vessel disease. 
Methods: Surveys, teleconferences, and an in-person workshop were used to identify gaps in 
knowledge and to develop tools for harmonizing imaging and analysis. 
Results: A framework for neuroimaging biomarker development was developed based on 
validating repeatability and reproducibility, biological principles, and feasibility of 
implementation. The status of current MRI biomarkers was reviewed. A website was created 
at www.harness-neuroimaging.org with acquisition protocols, a software database, rating 
scales and case report forms, and a deidentified MRI repository.  
Conclusions: The HARNESS initiative provides resources to reduce variability in 
measurement in MRI studies of cerebral small vessel disease. 
 
 
INTRODUCTION 
Vascular disease contributes to more than half of dementia cases, often in conjunction with 
Alzheimer’s disease pathology1. Most of the vascular brain injury is caused by cerebral small 
vessel disease (cSVD)2, which often goes clinically unrecognized until revealed by brain 
imaging. cSVD is strongly associated with cognitive impairment and future risk for cognitive 
decline and dementia3,4. One of the challenging but intriguing aspects of research in this field 
is that cSVD has diverse manifestations, including brain infarcts, lacunes, white matter 
hyperintensity (WMH) of presumed vascular origin, perivascular spaces, and microbleeds5. 
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Additionally, several promising new imaging biomarkers are emerging for the diagnosis and 
monitoring of patients, as well as for studies into etiology and pathophysiology6,7. 
The Standards for Reporting Vascular Changes on Neuroimaging (STRIVE)5 were an 
important first step to harmonize neuroimaging assessment of cSVD. Terms and definitions 
for common cSVD lesion types, reporting standards, and suggestions for acquisition 
protocols were provided, and are now commonly used in research practice. However, 
STRIVE did not address pathways for developing and validating new biomarkers, nor did it 
address sources of variability in measurement, which should be minimized to enhance the 
ability to detect biological differences in multicenter and longitudinal studies. 
To fully realize the potential of neuroimaging biomarkers of cSVD for use in larger 
scale, multicenter studies including clinical trials with cSVD endpoints, we created the 
Harmonizing Brain Imaging Methods for Vascular Contributions to Neurodegeneration 
(HARNESS) initiative. This initiative builds on the work of STRIVE by defining a 
framework for developing neuroimaging biomarkers of cSVD, reviewing the status of 
emerging neuroimaging biomarkers in this field, and developing and implementing 
standardized acquisition protocols and web-based repositories to facilitate multi-center 
research.  
 
METHODS 
HARNESS Group Composition 
HARNESS was funded by the international Joint Programme for Neurodegenerative Diseases 
initiative to address neuroimaging biomarkers in neurodegeneration and dementia. The 
HARNESS members were invited to participate based on contributions cSVD research 
including their participation in STRIVE, and to provide a balance of input from different 
geographic regions and research disciplines. HARNESS included 70 members from 29 
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institutions in 11 countries, representing disciplines including radiology, biomedical 
engineering, clinical trials, computer science, epidemiology, medical biophysics, neurology, 
stroke medicine and psychiatry. Members were surveyed to identify important needs for 
harmonizing neuroimaging methods for cSVD, and then subdivided into 11 working groups 
of 6-12 participants representing a range of disciplines, cSVD interests and location, to 
address these needs. The initiative commenced in July 2016 and culminated in an in-person 
conference in June 2017. Where appropriate, working groups identified relevant papers 
through literature searches, expert knowledge, and hand searching articles from reference 
lists, but formal systematic reviews and creation of evidence tables were considered out of 
scope.   
 
RESULTS 
Neuroimaging Biomarker Framework for cSVD 
We adopted the definition of a biomarker used by the Biomarkers Definitions Working 
Group8: “a characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention”. Inherent to this definition is that biomarkers may have different clinical 
purposes including diagnosis, prognosis, monitoring, and measuring treatment response. 
Biomarkers have been used as surrogate endpoints for clinical trials, meaning that the 
biomarker substitutes for or represents a manifestation of the clinical endpoint, when the 
biomarker is expected to predict “clinical benefit or harm based on epidemiologic, 
therapeutic, pathophysiologic, or other scientific evidence”9. This might be considered the 
highest level of qualification for a biomarker. However, biomarkers have other important 
uses for investigation, diagnosis, and monitoring of disease even if they do not predict 
treatment response. 
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Validation is required to determine whether a biomarker can be considered fit for a 
specific purpose. Some regulatory authorities, such as the U.S. Food and Drug 
Administration (FDA), define a formal process of biomarker qualification for use in 
evaluating therapeutics10. To our knowledge, no biomarker of cSVD, including WMH, 
lacunes, or microbleeds, has yet been submitted to and qualified by the US FDA for use in 
clinical trials, although they have been used as secondary endpoints in imaging substudies11. 
Qualification of an imaging marker that can be used as a trial endpoint would greatly 
accelerate the development of therapies for cSVD by improving selection criteria, reducing 
the size and cost of a trial and increasing the specificity of the outcome. 
To facilitate validation of cSVD biomarkers we present a framework for 
neuroimaging biomarker development in Figure 1, adapted from consensus recommendations 
from the European Society of Radiology12 and for development of imaging biomarkers for 
oncology13. Validation has technical aspects (e.g., can the same measurement be reproduced 
reliably on the same scanner or different scanners?), biological aspects (e.g., is the 
measurement different in patients with vs. without cSVD?), and feasibility of implementation 
(e.g., is the measurement practical and affordable?). In our version of this biomarker 
development framework, we define proof of concept as validation of measurement of a 
specific change or process (e.g., that arterial spin-labeling [ASL] MRI generates a signal that 
correlates with gold standard measurement of perfusion) while proof of principle refers to 
validation that the measurement distinguishes cases from controls or is associated with health 
outcomes (e.g., that ASL measured perfusion is different in cSVD patients than in controls 
and is associated with worse prognosis)12. We define proof of effectiveness as the ability to 
measure the marker across larger groups of patients at multiple sites12. Repeatability refers to 
the precision of repeated measurements under the same conditions using the same scanner 
(with high repeatability conferring greater power to detect smaller within-individual changes 
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over time, important for longitudinal studies), while reproducibility refers to the precision of 
replicate measurements on the same or similar objects (e.g. a phantom or human volunteers) 
using different scanners12,13. For visual assessments by human raters, intra-rater reliability 
refers to the precision of measurement by the same rater while inter-rater reliability refers to 
the precision of measurements across different raters. The Quantitative Imaging Biomarker 
Alliance (QIBA) offers recommendations for study design and statistical approaches to 
technical validation14. Validation typically begins with relatively small, cross-sectional 
studies at single centers to demonstrate proof of concept, proof of principle and initial 
technical validation, before expanding to longitudinal studies and multicenter studies to 
demonstrate proof of effectiveness and reproducibility. Feasibility is then demonstrated by 
incorporation of the biomarker into clinical radiological practice or by qualification for use in 
clinical trials. 
 
Survey of Current cSVD Biomarker Development with Specific Considerations for 
Selected Emerging Modalities  
CommonlyThe most studied neuroimaging biomarkers of cSVD are lacunes, WMH of 
presumed vascular origin, perivascular spaces and cerebral microbleeds. With the exception 
of perivascular spaces, Tthese lesions are typically described reported in routine radiology 
reports in clinical practice and have been incorporated as secondary imaging endpoints in 
some clinical trials. For these markers proof of concept, principle, and effectiveness have 
been established. Even so, longitudinal data on change over time and data on repeatability 
and reproducibility, so important for planning sample sizes in clinical trials, are relatively 
scant15,16.   
 A recent systematic review highlighted the gaps in knowledge in repeatability and 
reproducibility of measurements of cSVD lesions, focusing mostly on quantitative 
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biomarkers including volumes of WMH, lacunes, and brain17. The authors systematically 
searched the literature to identify information on scan-rescan repeatability (which they 
termed “within center reproducibility”) as well as the effects of scanner vendor, field 
strength, sequence choices, and coil type. They found that the amount of literature on 
repeatability and reproducibility varied widely by lesion type. The most literature was found 
on measures of brain volume, probably because brain atrophy is an important biomarker for 
many neurological diseases in addition to cSVD, such as Alzheimer’s disease, and because 
phantoms are available for measuring variations in geometric distortions across scanners. For 
WMH, lacunes, perivascular spaces, and microbleeds there was only sparse information on 
repeatability with relatively speaking the greatest amount of information on WMH 
measurements cross-sectionally, but no repeatability data on longitudinal measurements.  
Figure 2 provides an overview of the validation status of the best established cSVD 
markers as well as emerging modalities and techniques. Over time the list of neuroimaging 
biomarkers of cSVD has grown substantially as our knowledge of cSVD pathophysiology2, 
and ability to image it, has grown.  
Some markers have already received a large amount of attention, notably WMH 
(assessed visually or computationally), lacunes, and microbleeds (mainly visually with some 
emerging computational methods). Even so, some aspects of validation are lacking with few 
large comparisons of different volumetric tools, little longitudinal data, and none are yet 
adopted as confirmed surrogate outcomes in clinical trials. Nonetheless, they have already 
been the subject of many reviews16,17.  
Hence, the list of biomarkers discussed in detail here represents the subset that the 
HARNESS group selected as the next most promising for measuring unique aspects of cSVD 
pathophysiology, but that have so far received less attention. The list is not exhaustive. Future 
research will likely add more modalities and lesion types. For example, microinfarcts have 
10 
 
been visualized on MRI by several research groups and may be a frequent but 
underrecognized consequence of thrombosis or embolism of small arteries18. Additionally, 
future research  and may clarify that biomarkers currently on the list are a poor fit for some 
purposes.  
In the following sections, we review the state of imaging biomarker development for 
these selected emerging modalities, along with considerations for further development and 
harmonization. 
Structural Imaging: Perivascular spaces  
Perivascular spaces are rapidly emerging as a novel marker of cSVD and are defined as 
“fluid-filled spaces that follow the typical course of a vessel as it goes through grey or white 
matter”5. While long considered an innocuous phenomenon of aging, a converging body of 
proof of principle cross-sectional studies now suggests that a larger burden of perivascular 
spaces is associated with a higher likelihood of dementia, cognitive impairment, and stroke19-
21 More importantly, these associations are independent from established markers of cSVD. 
Longitudinal studies of the appearance of perivascular spaces or their enlargement over time 
are lacking; therefore, the rate at which these spaces change over time is essentially unknown. 
One study showed that the 5-year incidence of new large perivascular spaces (defined as ≥3 
mm diameter) in a general elderly population was 3.1%21, however this size exceeds the 
generally accepted current width boundary between perivascular spaces and lacunes5.  
There are few data on the repeatability of measurements of perivascular spaces and 
reproducibility of measurement across scanners. For one automated method, repeatability was 
excellent with intra-class correlations of 0.92 for basal ganglia and 0.87 for centrum 
semiovale22. In contrast, intra-rater and inter-rater reliability for visual rating scales have been 
published by several groups and should be expected to be good to excellent (i.e., with kappa 
values of 0.5 or higher or intra-class correlation coefficients of 0.6 or higher). Rating on T2-
11 
 
weighted sequences is favoured because perivascular spaces are well visible, but some 
studies have used high resolution T1-weighted sequences instead. In one study, ratings on 
T1-weighted and T2-weighted sequences showed excellent correlation (intraclass correlation  
>0.80)23. 
The HARNESS working group identified several difficulties in the quantification of 
perivascular spaces, which have so far hampered comprehensive understanding of their 
biological meaning. First, perivascular spaces, reflecting the virtual space between blood 
vessels and pia mater, by themselves are a physiologic finding. It is the enlargement of these 
spaces that can be visible on MRI that is considered non-physiologic. The question then 
remains what amount of enlargement should distinguish physiologic from non-physiologic 
perivascular spaces? Originally, a convenience threshold was chosen, such that any 
perivascular space visible on brain MRI was considered enlarged. However, increasing field 
strengths and other advances in imaging now allow much smaller perivascular spaces to 
become visible on MRI, indicating the need to use a more objective and reproducible 
threshold independent from imaging parameters. 
Second, since perivascular spaces are defined by their intricate relation to brain 
vessels, they are ubiquitous in all brain regions. Yet, the extent of enlargement is different 
across brain regions and should be taken into account in their quantification. A working 
upper width limit of 3 mm is widely used to discriminate perivascular spaces from small 
lacunes5, but for example it is well recognized that larger width perivascular spaces are 
sometimes seen in the substantia innominata. Radio-pathological correlation studies show 
that MRI can differentiate perivascular spaces from lacunes with good sensitivity and 
specificity using morphological and signal intensity information24, but more validation on 
correlations by region would be welcome. Similarly, the processes underlying their 
enlargement are thought to differ according to brain region; for example, in cerebral amyloid 
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angiopathy enlargement of perivascular spaces is seen in the centrum semiovale but not in the 
basal ganglia.25,26. 
Against this background, it is not surprising that the various efforts to quantify 
perivascular spaces have differed with respect to definition of enlargement, regions to be 
scored, and scoring system used23,27-30. While work continues to identify the key features of 
these rating systems with respect to similarities, dissimilarities, strengths, weaknesses, and 
‘translation’ from one rating system to the other, we recommend that investigators use the 
rating system most relevant to their population, or that they are most comfortable with, while 
having a core understanding how that specific rating system relates to others available in the 
literature. Raters should be trained on a standardized dataset with measurement of intra-rater 
and inter-rater reliability and report these measures in publications; training tools are 
available on HARNESS website.  
Parallel to this development of visual rating, there is now a strong focus on fully-
automated quantification of perivascular spaces. These efforts have so far been hampered by 
similar methodological considerations as outlined above, but the recent introduction of 
machine learning algorithms in brain imaging holds great promise in overcoming these 
barriers22,31. Just like automated quantification of WMH resulted in dramatic improvement in 
our understanding of their role in neurodegenerative diseases particularly at the voxel level, 
automated detection, volumetrics, shape, density and orientation of perivascular spaces could 
signify a paradigm shift in their position within the pantheon of cSVD markers. 
Structural Imaging: Atrophy in the context of cSVD  
Atrophy is now a well-established, measurable consequence of cSVD. Both cross-
sectional and longitudinal studies show proof of principle that total brain volume is lower in 
cSVD and decreases more quickly in persons with enlarging WMH. the context of 
progressive cSVD. The repeatability and reproducibility of brain volume measurements in the 
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context of cSVD has been reviewed recently17. Here, we highlight specific aspects to be 
considered when implementing atrophy measurements in cSVD studies.  
Given the complexity of brain anatomy, measures of brain volume should be obtained 
from 3D T1-weighted high-resolution isotropic sequences with quantitative computerized 
methods where possible. To capture chronic, final effects, the image acquisitions should be 
performed remotely in time (probably 90 days or longer) from the occurrence of acute brain 
lesions.  
At a given time point, volumetric measures reflect the sum of the individual’s 
maximum brain volume growth (estimated by the intracranial cavity volume), the effect of 
age, and that of multiple potential diseases including cSVD, overt stroke, and 
neurodegenerative diseases such as Alzheimer’s disease. Controlling for differences in head 
size, e.g. by expressing volumes as a fraction of intracranial volume or including intracranial 
volume as a covariate, is mandatory in single time point analyses. Although controlling for 
intracranial volume is not strictly necessary for longitudinal analyses, investigators may still 
want to analyze it as a proxy for original maximum brain size which reflects premorbid brain 
health and is associated with general intelligence32. In longitudinal analyses, the use of cross-
timepoint registration pipelines rather than repeated use of cross-sectional methods may 
reduce variability in measurement33,34 but the optimal approach remains to be confirmed.  
Methods involving registration to a common template should be used cautiously given 
that brains with cSVD, often exhibiting large ventricles and white matter atrophy, can register 
poorly to atlases based on healthy individuals. This is a particularly challenging problem 
when cSVD is accompanied by larger destructive intracerebral hemorrhages or infarcts. The 
impact of brain tissue lesions on the different methods to assess brain volume is often 
unpredictable35. In particular, the presence of extensive WMH can lead to erratic behavior of 
most algorithms,36,37 and if appropriate they should be masked. Additionally, algorithms may 
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variably segment fluid-filled cavities within the brain (lacunes and enlarged perivascular 
spaces) as cerebrospinal fluid, gray matter or white matter, requiring a systematic visual 
quality control of segmentation results35,38. There is consensus that cavities resulting from 
infarction should be excluded from These fluid-filled cavities should be excluded from brain 
tissue estimates5, depending on the question being asked; clearly, they do not represent 
spaces such as subarachnoid space or ventricles but nor do they represent normal brain tissue. 
They can be considered as part of the ‘total burden of brain injury’39 in some analyses. 
Quantitative methods are emerging that can estimate perivascular space volume; when such 
measurements are made we recommend that perivascular space volume be reported as a 
separate tissue class and not included in the total brain volume. Given the numerous sources 
of variation in gray to white contrast in cSVD, differential measures of gray and white matter 
volumes should be interpreted carefully40. The use of other computational volumetric 
markers, such as ventricle volumes, has not been validated in cSVD. All methods require 
visual checking and may need manual editing where automated segmentation has failed to 
identify the correct tissue. 
Diffusion imaging metrics 
Diffusion imaging provides of the diffusion of water molecules within brain tissue. 
There are a large variety of techniques to analyze these data. Diffusion-weighted imaging is 
positive (that is, shows increased signal) in the setting of recent infarction or microinfarction. 
Scalar measures describe diffusion properties on the voxel level, such as the extent or 
directionality. Diffusion tensor imaging (DTI) is the most useful model to derive these scalar 
metrics such as mean diffusivity (MD) or fractional anisotropy (FA). Tractography can be 
used to visualize fiber connections and analyze diffusion on the tract level. Global 
tractography in combination with graph theoretical network analysis allows to assess the 
impact of cSVD on the level of brain networks. 
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Proof of principle that diffusion imaging metrics can serve as biomarkers of cSVD is 
well established by multiple studies associating diffusion imaging indices derived from the 
white matter (WM) or normal-appearing WM (NAWM) with cSVD and cSVD risk factors. 
Most studies report cross-sectional associations between lower FA or higher MD and 
cognitive and gait impairments41,42 Mean diffusivity is readily measured in the whole brain, 
tissue subregions, regions of interest or tracts and shows the strongest associations with SVD 
lesion burden43. Recent, promising post-processing methods to increase the reliability and 
ease of extraction of diffusion imaging metrics include histogram-derived diffusion imaging 
metrics, such as the peak width of the skeletonized MD distribution (PSMD)44, and 
connectivity measures including ones based on network theory45-47. Lower brain connectivity 
in strategic network locations, such as long-distance fibers connecting so-called network 
‘hubs’, show promise for prediction of speed and executive functioning48,49. This is not an 
exhaustive list, as there are several other promising diffusion imaging acquisition and 
analysis methods which show promise for development as biomarkers of cSVD50,51. 
In contrast to the many cross-sectional studies, there are fewer studies evaluating 
diffusion imaging as a prognostic marker of disease progression.41 The LADIS study reported 
an association between NAWM MD at baseline and decline in processing speed,52 whereas 
the RUN DMC study found no association between baseline NAWM MD and cognitive 
decline53, or risk of dementia over 5 years54. Diffusion imaging-derived brain connectivity 
predicted conversion to dementia after 5 years55. Longitudinal studies of diffusion imaging 
change over time are at this time relatively scarce56-60 but promising, suggesting that change 
over time can be detected on diffusion imaging with similar sensitivity as change over time in 
WMH volume, requiring smaller sample sizes than required to detect atrophy or incident 
lacunes61. Progression over time in diffusion imaging metrics has been associated with 
increased risk of dementia58 and gait decline62. 
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The tissue correlate of altered diffusion metrics in cSVD is still debated. A recent 
study suggests that increased extracellular water content is a major contributor50. 
There are few studies on repeatability and reproducibility. The only study in patients 
with cSVD showed high reproducibility of PSMD in 7 patients with CADASIL scanned on a 
1.5T and 3T scanner (intraclass correlation 0.95)44. Other studies in healthy controls have 
shown good repeatability and reproducibility for FA and MD measurements (coefficient of 
variation ranging from 0.8 to 5.7%)63-65. Nonetheless, variation in scanner or scanner 
upgrades may bias measurements in longitudinal studies63; therefore, investigators ideally 
should avoid scanner upgrades or changing scanners between baseline and follow-up 
measurements in studies designed to detect small changes over time. Phantoms to estimate 
reproducibility are in development.66 
Perfusion and cerebrovascular reactivity  
Perfusion and cerebrovascular reactivity (CVR) approaches are highly relevant in cSVD 
research because reduced tissue perfusion and impaired CVR are hallmark pathological 
features. These physiological forms of imaging introduce a unique set of challenges for study 
design, given the large variability in acquisition methods for perfusion and especially CVR 
which are less well established compared to many structural imaging techniques. To image 
CVR, the investigator must choose among several experimental methods for stimulating 
changes in cerebral blood flow (CBF), as well as between several different acquisition types 
such blood oxygen level dependent (BOLD) or arterial spin labeling (ASL). Because the 
vascular signal comes from only a proportion of voxel contents (the blood volume fraction in 
grey matter accounts for 5 to 10% of the tissue volume), and for BOLD-related techniques 
the changes in hemoglobin oxygenation are relatively small, attention must be paid to ensure 
sufficient signal to noise ratio to generate images of adequate quality. 
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 Dynamic susceptibility contrast (DSC) and ASL are examples of MRI acquisitions 
that yield perfusion-weighted images; the former relies on an exogenous gadolinium contrast 
agent, while the latter uses magnetically labeled arterial blood water that is proximal to the 
imaging volume to label blood and produces quantitative perfusion maps typically expressed 
in units of mL/100g tissue/minute.  
ASL is a promising modality for repeated measure studies because it does not require 
administration of an exogenous intravenous contrast agent. A fraction of cSVD articles on 
perfusion have thus far used ASL67; cross-sectional studies, for example, provide proof of 
principle by showing that a pattern of reduced frontal perfusion was associated with increased 
WMH volume68. Longitudinal studies are less common, however, one 4-year follow-up study 
reported that global CBF decreases were associated with higher baseline WMH but that 
baseline CBF was not associated with greater WMH progression.69 Another longitudinal 
study found that while lower baseline CBF predicted appearance of new WMH at 18 months, 
change in CBF was not associated with new WMH70. Studies are needed on the association of 
baseline and longitudinal CBF and the prevalence and incidence of new brain infarcts and 
microinfarcts. Although white matter and subcortical tissue perfusion estimates are of 
particular interest in cSVD, these measurements are less robust than in grey matter when 
using ASL71 due to the lower CBF and longer arterial transit time.   
A validation study of ASL found higher repeatability for pseudo-continuous ASL 
compared with pulsed ASL or continuous ASL, with a coefficient of variation of 3.5% in 
gray matter and 8.0% in white matter72. There are few reproducibility studies across scanner 
types. One study found high reproducibility in eight volunteers scanned on two General 
Electric (GE) 3T scanners73. Another study found that sequence parameter differences had a 
larger effect than hardware or software differences on General Electric, Philips, and Siemens 
scanners74. Phantoms for ASL have been developed but not yet widely adopted75. 
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 Unlike physiological imaging during a single “baseline” state, CVR involves 
physiological provocation to measure a vasoactive response, typically by breathing medical 
air enriched with carbon dioxide gas. Technical and paradigm details and considerations have 
been recently reviewed76. Multi-contrast physiological imaging, combining perfusion and 
CVR maps in cSVD, is a promising technique77. At this time, relatively few CVR studies 
have focused explicitly on cSVD78. However, CVR imaging is being exploited as an imaging 
endpoint to assess the efficacy of vasodilatory drugs in a dose escalation trial79. CVR appears 
to be a promising prognostic biomarker of cSVD brain changes, for example as revealed by 
one longitudinal study that found impaired regional CVR was predictive of WMH lesion 
expansion at one-year follow-up80. A four-year longitudinal study showed that age-related 
decreases in CVR were associated with steeper declines in processing speed and episodic 
memory but not working memory or reasoning; however, the degree to which enlarging 
WMH or new infarction progressive cSVD may have caused been associated with these 
changes was not assessed. The BOLD-response to a visual stimulus has been shown to be a 
possible biomarker for CAA and could be a more easily implemented, well-tolerated 
alternative means to measure CVR, but is is limited to the occipital lobe81-83 and has not been 
compared directly to CVR measurement based on hypercapnia. 
 The repeatability of CVR measurements has been investigated in healthy controls but 
not patients with cSVD. In a study of 15 controls, the coefficient of variation ranged from 
7.3% to 42.9% across 16 regions of interest including cortical and subcortical grey matter and 
white matter84. The coefficient of variation was lower when using a paradigm that averaged 
two three-minute blocks of CO2 inhalation rather than three one-minute blocks
84. 
 A consensus group has provided recommendations for ASL imaging protocols85; 
however, long-label and long-delay ASL approaches may prove superior for CBF 
measurement in the white matter and subcortical gray matter. Multicenter studies using 
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scanners from different vendors seems justifiable as long as key methods (including choice of 
pseudo-continuous ASL, readout strategy, labeling duration, and post-labeling delay time) are 
kept constant. For CVR imaging, there are a greater diversity of methods and the different 
methods may suit specific patient populations. One published protocol84 using three-minute 
CO2 blocks is being used in a multicenter trial. 
Blood-brain barrier integrity 
Although proof-of-concept evidence is very limited, proof-of-principle evidence from cross-
sectional clinical studies suggests that blood-brain barrier (BBB) dysfunction determined by 
MR is associated with imaging features of cSVD, and that BBB leakage may contribute to 
tissue damage, development of cSVD features and long-term adverse outcomes86,87. 
Therefore, BBB permeability is an important target of measurement in studies of 
pathophysiology and treatment evaluation. 
Dynamic contrast-enhanced MRI (DCE-MRI) using a standard dose of a gadolinium-
based contrast agent is presently the most promising technique for quantitative imaging of 
subtle leakage86, and has been applied in several studies of cSVD and related conditions.86,88-
91 However, while the technique is well-established in other conditions such as brain tumours, 
particular challenges emerge in cSVD due to the slow rate of leakage. For qualitative 
assessment, gadolinium-based contrast agent (GBCA) enhancement of cerebrospinal fluid on 
T2-weighted fluid attenuated inversion recovery (FLAIR) and T1-weighted imaging may 
provide a practical, though non-specific, alternative92,93. Other potential methods are difficult 
to quantify (e.g. dynamic susceptibility contrast MRI),94 employ ionising radiation,95,96 or are 
at an early stage of development (compartmental ASL modelling97-99). Nevertheless, DCE-
MRI is not routinely used in cSVD studies due to practical impediments (long scan time, 
exogenous contrast), lack of widespread expertise, and technical and physiological 
complexities and confounds100,101.   
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There are few studies of BBB permeability change over time in cSVD. A single study 
of 22 subjects with high WMH burden reported little overlap between regions of high white 
matter permeability between the first and second scan, but that high permeability was often 
seen along the border of WMH at either time102. 
Because there is no reliable convenient reference method for quantifying subtle BBB 
permeability, studies comparing DCE-MRI measurements with other measures of BBB 
integrity are few and inconclusive103,104. The need for a second gadolinium administration is a 
barrier to conducting studies on repeatability, but one study showed good evidence of 
repeatability with coefficient of variation of 11.6 % for white matter and 14.4 % for gray 
matter at 3T105. Reproducibility across different MR hardware has not been investigated. 
Based on theoretical considerations and experimental observations, it is likely that 
measurements are influenced by MR field strength, scanner stability, spatial resolution, pulse 
sequence parameters, acquisition time, GBCA type, and pharmacokinetic model100,101,106,107. 
The diversity of acquisition and analysis protocols described (sometimes incompletely) in the 
literature is, therefore, a key impediment to the interpretation and comparison of data from 
different studies and centres. 
Our recommendation for future studies is to use a three-dimensional, MR acquisition 
with wide spatial coverage, pre-contrast T1 measurement, a minimum temporal resolution of 
around one minute and minimum DCE scan time of 15 minutes108. A vascular input function 
should be measured in the venous sinuses and the permeability-surface area product PS for 
tissue regions or, where feasible, individual voxels should be estimated using an appropriate 
pharmacokinetic model, typically the Patlak model109; simulations may be performed to 
assess accuracy and precision. Results should be interpreted carefully, particularly when 
comparing data from different research groups or scanners. We identify three priorities for 
the development of this biomarker: (i) agreement by the wider cSVD and dementia imaging 
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research community on an open-access, dynamic consensus protocol for DCE-MRI 
measurements of slow BBB leakage, (ii) acquisition of data on repeatability and 
reproducibility, and (iii) studies to assess accuracy, including theoretical work, comparison 
with independent measures of BBB integrity, and validation using MR test objects and 
histology. Further technical development to increase accuracy and precision, as well as 
continued development of alternative methods are also encouraged. 
Ultra high field MRI 
Ultra-high field MRI, in particular 7T MRI, is emerging as a new tool in cSVD research. The 
higher resolution, different tissue contrasts, and better signal to noise ratios of 7T MRI allow 
the investigator to probe aspects of cSVD that are difficult to assess at lower field strength. In 
addition to enhanced sensitivity for cSVD lesions such as microinfarcts and microbleeds and 
more precise assessment of atrophy18,110, with 7T MRI it is possible to actually visualize the 
small vessels111.  From both perforating arteries and veins features such as vessel density, 
length, and tortuosity can be resolved.111,112. Additionally, different aspects of vascular 
function, including blood flow, pulsatility of flow in small penetrating arteries (a possible 
indicator of vascular stiffness), vascular reactivity to vasoactive agents (e.g carbon dioxide) 
or neuronal stimulation (i.e. functional MRI), can be assessed, making it possible to probe 
cSVD at the level of the small vessels themselves111. 
Despite the potential for of 7T MRI for cSVD, important steps have to be taken to 
validate these novel techniques. Of note, EUFIND (the European Ultrahigh-Field Imaging 
Network in Neurodegenerative Diseases), another JPND initiative, has the goal of 
harmonizing 7T MRI protocols across more than 20 centres from Europe and the US.  
 
Tools to Facilitate cSVD Biomarker Development and Harmonization 
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 The HARNESS initiative focused on three areas to provide tools for harmonization: 
MR acquisition, post-processing, and common repositories for training and validation. These 
tools are made available to the research community at www.harness-neuroimaging.org. 
 The HARNESS website provides fully specified MR acquisition protocols suitable for 
research studies that include a focus on cSVD. Given the diversity of manifestations of cSVD 
and hypotheses that can be tested, there is no single MR acquisition protocol that can quantify 
all aspects of cSVD and therefore investigators must make choices regarding protocol 
composition, also accounting for issues of feasibility including acquisition time and cost. 
Therefore, instead of a single protocol the HARNESS website provides several options that 
meet these criteria: a) they adhere to STRIVE5, b) they are suitable for identifying canonical 
cSVD lesions types--lacunes and WMH of presumed vascular origin, recent small infarcts, 
microbleeds, atrophy, and DTI changes, c) they have been tested on more than one scanner as 
part of an established multicenter study and d) the protocol developers are willing to share the 
protocol freely. There are also links to other websites and useful repositories of information. 
Currently, protocols are available from the SVD@target study84 (ISRCTN10514229) 
and the Canadian Dementia Imaging Protocol113, with plans to add the protocol from the U.S. 
National Institute of Neurological Disorders and Stroke MarkVCID Biomarker Consortium 
(https://markvcid.partners.org/) once it has been fully specified and tested. Sequence 
parameters with exam cards are provided for 3T for most of the major vendors including 
General Electric, Phillips, and Siemens. The protocols are suitable for prospective research 
studies with quantitative imaging biomarkers but probably exceed most clinical stroke 
protocols in terms of acquisition time, spatial resolution, and inclusion of DTI. They have 
been implemented successfully in multicenter studies at research sites, but nonetheless may 
not be feasible for multicenter studies performed at predominantly clinical scan sites where 
the intent is to leverage clinical imaging without a focus on quantitative biomarkers.  
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 Reducing imaging variability may be enhanced by following consensus 
recommendations17 to perform automated quality checks for acquisition parameters and 
monitoring of images for artefacts, correction for gradient nonlinearities, a well-defined 
method for subject’s positioning in the scanner, and a clear strategy for hardware replacement 
when needed.  
 The HARNESS software database provides a searchable source for information on 
downloadable software tools for processing MR data for cSVD quantitative biomarkers, such 
as for segmenting WMH. There are many existing software libraries for neuroimaging 
analysis, but only HARNESS focuses exclusively on cSVD. Site users can search for 
software by image modality, measurement type, key words, availability (i.e. by download or 
by request to the developer), or operating system. Software developers control their own 
entries via password-protected accounts, and must make their software available according to 
their own terms by providing a link or through contacting the developer. We are actively 
recruiting developers with tools to sell or share. Developers may access the site for 
information on how to create accounts. 
 To aid visual review for cSVD lesions according to STRIVE, the HARNESS site 
makes downloadable electronic documents available including validated visual rating scale 
scores and instructions, case report forms, and training slides. 
 Training readers and software algorithms requires access to independent MR datasets 
for measurements. The HARNESS site includes a web-based repository with completely de-
identified 3T MR data showing lacunes, WMH, microbleeds, and cortical superficial 
siderosis from patients with TIA, minor ischemic stroke, and cerebral amyloid angiopathy, 
with consensus “gold standard” measurements for comparison. This repository will be useful 
for independently confirming reliability of measurements within and across research groups, 
and for derivation and validation of computerized algorithms for quantitative measurement 
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(e.g. for segmenting WMH to determine location and overall volume) as well for comparing 
WMH algorithms against an independent standard. 
 
SUMMARY AND CONCLUSIONS 
 The HARNESS initiative was a multidisciplinary consensus process with input from a 
large number of neuroimaging researchers investigating cSVD. Our group developed a 
framework for neuroimaging biomarker development closely aligned with those proposed in 
other areas of imaging research. The HARNESS website (www.harness-neuroimaging.org) 
was created to facilitate harmonized neuroimaging methods for cSVD research.  The site 
includes cSVD-appropriate MR acquisition protocols aligned with STRIVE, a searchable 
database of softwares for analyzing brains with cSVD, visual rating scales and case report 
forms, and a repository of 100 deidentified scans demonstrating different cSVD lesion types. 
These tools and resources are made available to the research community via the site and can 
be easily updated by contributors. 
 In this rapidly evolving field, we found that the degree of biomarker validation—
technical, biological and clinical, and feasibility—varied by cSVD lesion and measurement 
type. In general, visually diagnosed cSVD lesions such as lacunes, WMH, and microbleeds 
have the greatest amount of clinical validation including as prognostic markers and data are 
available on incidence andchange over time, and are already being used in multicenter studies 
and reported in routine clinical practice. Even so, none of these markers has yet been 
qualified for use in clinical trials by regulatory agencies, and more work is needed to 
standardize and compare current volumetric tools. Other markers are at a less advanced stage 
of biomarker development. Atrophy has been extensively studied but almost always in the 
context of Alzheimer’s disease and not cSVD. Among the emerging cSVD markers there are 
relatively more data on diffusion imaging and perivascular space imaging, but more 
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longitudinal data and multicenter data on reproducibility are needed. Measurements of brain 
perfusion, vascular reactivity, and blood-brain barrier integrity are promising but are at an 
even earlier stage of development. For these cSVD manifestations innovation to overcome 
technical and feasibility barriers, rather than harmonizing to a best protocol, is the most 
important next step in development. 
 We found that technical validation often lagged clinical validation. However, 
estimates of repeatability and reproducibility are critically important to estimate minimum 
detectable differences over time and variability in measurement in multicenter studies, 
essential for sample size calculations for multicenter longitudinal trials. This lag in technical 
validation likely reflects the difficulty in obtaining funding for technical studies compared to 
clinical studies, the burden on research subjects to undergo multiple scans, and the general 
lack of non-human phantoms for studies of reproducibility. In contrast to volumetric imaging 
and functional MRI, phantoms for other measurements are less well developed. One research 
group has developed a phantom for iron deposits that mimic mineral deposits and 
microbleeds, not currently available for purchase114; otherwise, we are not aware of any other 
phantoms that recreate specific aspects of cSVD. Technical validation for neuroimaging 
biomarkers of cSVD would be enhanced by creating funding opportunities specifically for 
this purpose. 
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Figure 1. Imaging Biomarker Development Framework for Cerebral Small Vessel Disease 
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Figure 2. Schematic overview of neuroimaging biomarker development status for cerebral 
small vessel disease 
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Figure 2 Legend: Green light indicates validation data from two or more studies from 
independent research groups; Yellow light indicates support from a single study or 
conflicting evidence from multiple studies; Red light indicates there is currently insufficient 
evidence. WMH, white matter hyperintensities of presumed vascular origin; CMB, cerebral 
microbleeds; PVS, perivascular spaces; DTI, diffusion tensor imaging; BBB, blood-brain 
barrier. Proof of concept: evidence that the marker measures a specific change or process 
related to cerebral small vessel disease.  Proof of principle/ Mechanism: evidence that the 
marker differs between patients with and without cerebral small vessel disease. Proof of 
effectiveness: evidence from larger scale multiple center studies that the marker differs 
between patients with and without cerebral small vessel disease. Repeatability: precision of 
repeated measurements under the same conditions using the same scanner. Reproducibility: 
replicate measurements on the same or similar objects (e.g. a phantom or human volunteers) 
in different locations using different scanners. Longitudinal: rate of change over time has 
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been defined. Monitoring: evidence that longitudinal change in the marker is associated with 
progression of cerebral small vessel disease. Surrogate: evidence that change in the marker is 
strongly associated with clinical outcomes in cerebral small vessel disease, such that changes 
in the marker could be considered a substitute for a clinical endpoint.  
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special section.  Well written, authoritative and clear. 
Response: Thank you. 
 
Reviewer #2 
This is an important and well-written study with a direct end-result, a website, that directly 
will benefit further research on the topic. Thanks for a very well written study! 
Response: Thank you. 
1. "The most studied neuroimaging biomarkers of cSVD are lacunes, WMH of presumed 
vascular origin, perivascular spaces and cerebral microbleeds " Sure, these markers are 
certainly the most studied, but perivascular spaces has not been studied to the same degree 
as the other mentioned markers. I suggest not including "most studied" as it is not based 
on evidence, and may be inaccurate. "Commonly studied" may be another way to 
accurately phrase this. 
Response: We have revised the sentence as follows (page 8): “Commonly studied neuroimaging 
biomarkers of cSVD are lacunes, WMH of presumed vascular origin, and cerebral microbleeds. 
These lesions are typically reported in routine radiology clinical practice and….” 
2.  In the atrophy section perivascular spaces are briefly touched upon with regards to 
spaces not to be included in the final brain segmentation volume. Is there however software 
that measures the total volume of perivascular spaces? Please include a brief sentence on 
this. 
Response: Software to calculate perivascular spaces are just beginning to be developed. An 
example of one such method is provided in the section on perivascular spaces (reference 31). 
However, perivascular space volume measurement is currently not implemented in the most 
commonly used packages for brain segmentation, such as FSL or Freesurfer. We have made a 
revision as follows (page 14): “There is consensus that cavities resulting from infarction should 
Response
be excluded from brain tissue estimates5 depending on the question being asked; clearly, they do 
not represent spaces such as subarachnoid space or ventricles but nor do they represent normal 
brain tissue. They can be considered as part of the ‘total burden of brain injury’38 in some 
analyses. Quantitative methods are emerging that can estimate perivascular space volume30; 
when such measurements are made we recommend that perivascular space volume be reported as 
a separate tissue class and not included in the total brain volume.” 
3. "progressive cSVD." Define progressive cSVD 
Response: We have revised the manuscript in two places to be more specific. On page 11 we 
now write: “Both cross-sectional and longitudinal studies show proof of principle that total brain 
volume is lower in cSVD and decreases more quickly in persons with enlarging WMH.” On page 
18 we now write: “A four-year longitudinal study showed that age-related decreases in CVR 
were associated with steeper declines in processing speed and episodic memory but not working 
memory or reasoning; however, the degree to which enlarging WMH or new infarction may have 
been associated with these changes was not assessed.” 
4. Diffusion imaging metrics is discussed but acute microinfarcts are not mentioned. This 
may be worthwhile including. 
Response: We have added this sentence acknowledging the important role of diffusion weighted 
imaging in identifying acute infarction, including microinfarction (page 14): “Diffusion-
weighted imaging is positive (that is, shows increased signal) in the setting of recent infarction or 
microinfarction.”  
Additionally, we have revised the section on the Survey of Current SVD Biomarker 
Development to cite a recent review of microinfarcts published in Lancet Neurology (page 9, 
reference 18): “Future research will likely add more modalities and lesion types. For example, 
microinfarcts have been visualized on MRI by several research groups and may be a frequent but 
underrecognized consequence of thrombosis or embolism of small arteries.” 
5. Interesting section on perfusion. It would be great if one sentence or two could be 
included on cortical microinfarcts and their association with brain perfusion. 
Response: Several lines of evidence point to an association between hypoperfusion and cortical 
microinfarcts including experimental animal studies, and human pathology studies that identify a 
higher frequency of microinfarction at the borderzones of cerebral arterial territories. However, 
to our knowledge there are not yet human in vivo data that directly associate hypoperfusion with 
the presence of microinfarction. Establishing the role of hypoperfusion in causing microinfarcts 
is listed as a future research direction in a recent review of microinfarcts published in Lancet 
Neurology (reference 18). We have revised the perfusion section to cite the need for longitudinal 
studies on perfusion and microinfarcts (page 19): “Studies are needed on the association of 
baseline and longitudinal CBF and the prevalence and incidence of new brain infarcts and 
microinfarcts.” 
6. "attention must be paid to ensure sufficient signal to noise to generate images of 
adequate quality" Add ratio after "signal to noise" 
Response: We made the suggested revision (page 16). 
7. Write out GBCA first time it is used since this is not an imaging journal per se. 
Response: We have spelled it out: “gadolinium-based contrast agent” (page 19). 
8. General: All the subtitles under results include imaging techniques, however 
perivascular spaces stand out in that they are a marker of cSVD. I think the paper would 
benefit from PVS being part of the atrophy section. Or maybe under a separate title named 
structural imaging. 
Response: To better harmonize the sections we have moved the perivascular spaces section to 
follow atrophy and renamed these sections “Structural imaging: brain atrophy” and “Structural 
imaging: perivascular spaces”. 
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